Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin
- PMID: 10481831
- DOI: 10.1016/S0893-133X(98)00124-9
Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin
Abstract
Cholecystokinin (CCK) is an abundant neurotransmitter in brain. Its functional significance in humans is incompletely understood, but it may modulate activity in the hypothalamic-pituitary-adrenal (HPA) axis. To explore this hypothesis, we examined the effects of varying doses (0 to 0.8 microgram/kg) of the CCK-B agonist pentagastrin on adrenocorticotropin (ACTH) and cortisol release in healthy human subjects. We also examined anxiety, heart rate (HR), and blood pressure (BP) responses. Pentagastrin induced large (up to 520% increase over baseline), significant and very rapid, dose-dependent elevations in ACTH and cortisol levels. Significant elevations in HR and BP were seen at all doses, without clear dose-response relationships. Anxious distress and symptom responses were also somewhat dose dependent; but hormonal responses were more robustly linked to pentagastrin dose than to these subjective measures. The HPA axis response to the CCK-B agonist pentagastrin may be a direct pharmacological effect. Further work is needed to determine the mechanisms and the physiological significance of CCK-mediated modulation of the human neuroendocrine stress axis.
Similar articles
-
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.Neuropsychopharmacology. 2001 Feb;24(2):161-9. doi: 10.1016/S0893-133X(00)00182-2. Neuropsychopharmacology. 2001. PMID: 11120398 Clinical Trial.
-
Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin.Psychiatry Res. 2004 May 30;126(3):189-95. doi: 10.1016/j.psychres.2004.01.009. Psychiatry Res. 2004. PMID: 15157745 Clinical Trial.
-
Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.Arch Gen Psychiatry. 2005 Jun;62(6):668-75. doi: 10.1001/archpsyc.62.6.668. Arch Gen Psychiatry. 2005. PMID: 15939844 Clinical Trial.
-
HPA axis activity in patients with panic disorder: review and synthesis of four studies.Depress Anxiety. 2007;24(1):66-76. doi: 10.1002/da.20220. Depress Anxiety. 2007. PMID: 16845643 Review.
-
Cholecystokinin and panic disorder: past and future clinical research strategies.Scand J Clin Lab Invest Suppl. 2001;234:19-27. Scand J Clin Lab Invest Suppl. 2001. PMID: 11713976 Review.
Cited by
-
Transcriptome profiles of hypothalamus and adrenal gland linked to haplotype related to coping behavior in pigs.Sci Rep. 2019 Sep 10;9(1):13038. doi: 10.1038/s41598-019-49521-2. Sci Rep. 2019. PMID: 31506580 Free PMC article.
-
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.Psychopharmacology (Berl). 2007 Jul;192(4):479-87. doi: 10.1007/s00213-007-0738-7. Epub 2007 Feb 23. Psychopharmacology (Berl). 2007. PMID: 17318504 Clinical Trial.
-
Effect of cholecystokinin on cytokines during endotoxic shock in rats.World J Gastroenterol. 2001 Oct;7(5):667-71. doi: 10.3748/wjg.v7.i5.667. World J Gastroenterol. 2001. PMID: 11819851 Free PMC article.
-
Emotional perception modulated by an opioid and a cholecystokinin agonist.Psychopharmacology (Berl). 2008 Apr;197(2):295-307. doi: 10.1007/s00213-007-1032-4. Epub 2007 Dec 11. Psychopharmacology (Berl). 2008. PMID: 18071677 Clinical Trial.
-
Neurobiology of panic and pH chemosensation in the brain.Dialogues Clin Neurosci. 2011;13(4):475-83. doi: 10.31887/DCNS.2011.13.4/jwemmie. Dialogues Clin Neurosci. 2011. PMID: 22275852 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources